93 trends tracked about this subject — the full history, oldest to newest below.
AstraZeneca has acquired St. Louis-based biotech Omniose to add its proprietary bioconjugation platform to the company's infectious disease vaccine pipeline.
9 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
A cheap B‑vitamin pill shows promise in easing psoriasis symptoms, sparking hope for millions with the incurable skin disease
A human subject has received an injection of an AI-designed virus intended to target antibiotic-resistant bacteria.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Anthropic is expanding its biotech footprint by acquiring a stealth, one-person startup operated by a pseudonymous Twitter user.
Artiva Biotherapeutics is discontinuing its autoimmune cell therapy and cutting 94 percent of its staff following patient deaths.
China is calling for the United States to halt proposed expansions of outbound investment curbs targeting high-tech sectors and biotech deals.
Scientists have conducted the first-ever test of prime editing to alter DNA directly inside the human body, potentially offering a cure for genetic diseases.
The United States Treasury proposes new rules adding biotechnology to its outbound investment security program to target China.
11 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
The United States Treasury proposes new rules targeting high-tech and biotech investments in China.
A startup deploys an artificial intelligence-designed virus in a human patient for the first time.
Recent scientific research details a cellular reprogramming breakthrough that reverses decades of biological aging in human cells.
5 news sources are covering this Science story right now — PULSE is tracking how fast it spreads.
China proposes new export controls spanning artificial intelligence, biotechnology, and solar power amid national security risks.
An AI-powered system designed by a Nobel laureate's institute creates molecular scissors that target specific proteins.
Harvard Medical School introduces a new screening platform to identify genes possessing tissue-rejuvenation potential.
Colossal Biosciences unveils an AI platform to accelerate de-extinction science alongside major genetic milestones.
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Engineered yeast could become the sticky cement that builds the first 3‑D‑printed habitats on Mars.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
AstraZeneca asserts independence for post-2030 growth while investing over $1 billion in a new robotics-driven R&D hub in Cambridge, Massachusetts.
Vaxcyte stock surges following phase 3 trial results for its pneumococcal vaccine candidate in a lucrative market.
Genentech has entered a global license agreement with Alector for a preclinical brain-penetrant enzyme replacement therapy targeting Parkinson's disease.
Fierce Biotech has unveiled its 2026 'Fierce 15' list, highlighting the most innovative and promising private biotechnology companies of the year.
Novartis secures the rights to Abogen’s mRNA T cell engager in a massive $575 million upfront transaction.
Recent coverage examines whether new genome editors are surpassing traditional CRISPR technology.
Novartis has agreed to a massive new mRNA drug deal with Chinese startup Abogen worth up to $7.8 billion.
2 news sources are covering this Technology story right now — PULSE is tracking how fast it spreads.
A multi-cancer early detection blood test draws investor enthusiasm and trial data coverage across major financial and health outlets.
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
uniQure stock plummets alongside partner shares following disappointing clinical data from a Huntington's gene therapy trial.
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Adicet Bio's experimental CAR-T therapy sparks early lupus remissions, drawing widespread industry attention.
Endpoints News has revealed the 2026 Endpoints 11, spotlighting the most exciting startups currently shaping the biotechnology landscape.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Novo Nordisk strikes a $1.3 billion deal with Nanexa to secure long-acting obesity injection technology.
9 news sources are covering this Technology story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
AI startup Basecamp Research raises $140 million in an oversubscribed Series C funding round.
Novartis has expanded its portfolio by licensing a preclinical radioligand asset from BoomRay in a $900M transaction.
6 news sources are covering this Science story right now — PULSE is tracking how fast it spreads.
Scientific coverage highlights virtual cells built from 4D AI models and digital twins accelerating drug discovery.
2 news sources are covering this Science story right now — PULSE is tracking how fast it spreads.
An artificial intelligence-designed drug makes patients' blood look biologically younger, according to a new study.
Recent coverage examines how artificial intelligence transforms biological research, raising urgent questions about safety and guardrails.
Takeda Pharmaceutical's R&D chief Andy Plump is set to retire in June 2027 following a period of significant pipeline reorganization and regulatory success.
Bristol Myers Squibb reports successful Phase 2 results for its next-generation GPRC5D-directed CAR-T therapy targeting heavily treated myeloma patients.
A clinical trial has indicated that a drug developed through artificial intelligence may have the capacity to make patients biologically younger.
Roivant Sciences stock surges as its experimental inhaled lung disease drug hits mid-stage study goals.
Inhibrx claims a first-of-its-kind win for a long-sought immunotherapy target with new clinical data.
AstraZeneca reports significant Phase III trial wins for Tozorakimab, a COPD drug showing broad benefits for current and former smokers.
A new study suggests that a drug developed through artificial intelligence may have the potential to slow the biological process of aging.
An AI-designed drug candidate for lung disease, Rentosertib, has shown potential to reverse biological aging markers in early clinical data.
Personalized mRNA cancer vaccines are gaining momentum following Phase III success in melanoma and expanded global clinical trials.
Roche has secured a global licensing pact with Simcere Zaiming for an experimental B-cell-targeting antibody.
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.